Claims for Patent: 10,351,625

Summary for Patent: 10,351,625

Title:	Anti-PVRIG antibodies and methods of use
Abstract:	The present invention is directed to anti-PVRIG antibodies and methods of using same.
Inventor(s):	White; Mark (Antioch, CA), Kumar; Sandeep (San Bruno, CA), Chan; Christopher (South San Francisco, CA), Liang; Spencer (San Mateo, CA), Stapleton; Lance (Oakland, CA), Drake; Andrew W. (Mountain View, CA), Gozlan; Yosi (Tel Aviv, IL), Vaknin; Ilan (Tel Aviv, IL), Sameah-Greenwald; Shirley (Kfar Saba, IL), Dassa; Liat (Tel Aviv, IL), Tiran; Zohar (Oranit, IL), Cojocaru; Gad S. (Tel Aviv, IL), Presta; Leonard (San Francisco, CA), Theolis; Richard (Santa Cruz, CA)
Assignee:	Compugen Ltd. (Holon, IL)
Application Number:	15/896,040
Patent Claims:	1. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises: i) a heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and ii) a light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1453, wherein a subset of said T-cells of said patient are activated. 2. A method according to claim 1 wherein said anti-PVRIG antibody comprises the heavy chain variable domain of SEQ ID NO:1434 and the light chain variable domain of SEQ ID NO:1453. 3. A method according to claim 2 wherein said anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations. 4. A method according to claim 3 wherein said anti-PVRIG antibody comprises the CL region of human kappa 2 light chain. 5. A method according to claim 2 wherein said T-cells are cytotoxic T-cells (CTLs). 6. A method according to claim 2 wherein said T-cells are selected from the group consisting of CD4.sup.+ T-cells and CD8.sup.+ T-cells. 7. A method according to claim 2 wherein said activation is measured as an increase in interferon-.gamma. production and/or an increase in cytokine secretion. 8. A method according to claim 1 wherein said anti-PD-1 antibody is pembrolizumab. 9. A method according to claim 1 wherein said anti-PD-1 antibody is nivolumab. 10. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises: i) a heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and ii) a light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1462, wherein a subset of said T-cells of said patient are activated. 11. A method according to claim 10 wherein said anti-PVRIG antibody comprises the heavy chain variable domain of SEQ ID NO:1447 and the light chain variable domain of SEQ ID NO:1462. 12. A method according to claim 11 wherein said anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations. 13. A method according to claim 11 wherein said anti-PVRIG antibody comprises the CL region of human kappa 2 light chain. 14. A method according to claim 10 wherein said T-cells are cytotoxic T-cells (CTLs). 15. A method according to claim 10 wherein said T-cells are selected from the group consisting of CD4.sup.+ T-cells and CD8.sup.+ T-cells. 16. A method according to claim 10 wherein said activation is measured as an increase in interferon-.gamma. production and/or an increase in cytokine secretion. 17. A method according to claim 10 wherein said anti-PD-1 antibody is pembrolizumab. 18. A method according to claim 10 wherein said anti-PD-1 antibody is nivolumab. 19. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises: a) a heavy chain variable domain comprising: i) a vhCDR1 comprising SEQ ID NO:885; ii) a vhCDR2 comprising SEQ ID NO:886; iii) a vhCDR3 comprising SEQ ID NO:887; and b) a light chain variable domain comprising: i) a vlCDR1 comprising SEQ ID NO:889; ii) a vlCDR2 comprising SEQ ID NO:890; iii) a vlCDR3 comprising SEQ ID NO:891, wherein a subset of said T-cells of said patient are activated. 20. A method according to claim 19 wherein said anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations. 21. A method according to claim 19 wherein said anti-PVRIG antibody comprises the CL region of human kappa 2 light chain. 22. A method according to claim 19 wherein said T-cells are cytotoxic T-cells (CTLs). 23. A method according to claim 19 wherein said T-cells are selected from the group consisting of CD4.sup.+ T-cells and CD8.sup.+ T-cells. 24. A method according to claim 19 wherein said activation is measured as an increase in interferon-.gamma. production and/or an increase in cytokine secretion. 25. A method according to claim 19 wherein said anti-PD-1 antibody is pembrolizumab. 26. A method according to claim 19 wherein said anti-PD-1 antibody is nivolumab. 27. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises: a) a heavy chain comprising: i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1434 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and b) a light chain comprising: i) a VL-CL, wherein the VL is SEQ ID NO:1453 and wherein the CL region is from human kappa 2 light chain. 28. A method according to claim 27 wherein said hinge region optionally comprises mutations. 29. A method according to claim 27 wherein said anti-PD-1 antibody is pembrolizumab. 30. A method according to claim 27 wherein said anti-PD-1 antibody is nivolumab. 31. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises: a) a heavy chain comprising: i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1447 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and b) a light chain comprising: i) a VL-CL, wherein the VL is SEQ ID NO:1462 and wherein the CL region is from human kappa 2 light chain. 32. A method according to claim 31 wherein said hinge region optionally comprises mutations. 33. A method according to claim 31 wherein said anti-PD-1 antibody is pembrolizumab. 34. A method according to claim 31 wherein said anti-PD-1 antibody is nivolumab.

Details for Patent 10,351,625

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2035-02-19
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2035-02-19
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2035-02-19